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Seroconversion of immunoglobulin A (IgA) and immunoglobulin G (IgG) (4-fold rise) to rotavirus non-
structural protein 4 (NSP4) was determined, by use of enzyme-linked immunosorbent assay with fusion
proteins glutathione S–transferase (GST)–NSP4 from strains SA11 (A), 116E (B), and RRV (C), in 40 children
with acute rotavirus gastroenteritis and in 30 with the same disease due to other pathogens. The IgG sero-
conversion rates in the rotavirus group were 67.5%, 70%, and 60% when recombinant (r) NSP4A, -B, and
-C, respectively, were used as antigen in the assay, and, for rotavirus-uninfected children, rates were 10%,
13%, and 7%. IgA seroconversion occurred in 57%, 70%, and 50%, respectively, of children with rotavirus
gastroenteritis; in rotavirus-uninfected children, 1 child each seroconverted to the different rNSP4s. Among
9 children infected with strain NSP4A, 7, 6, and 5 children showed IgG seroconversion, and, among 18 infected
with NSP4A, -B, and -C, 16, 17, and 15, respectively, showed IgG seroconversion. Between NSP4A-infected
and NSP4B-infected children, IgA responses were similar to IgG responses. In conclusion, significant NSP4-
specific antibody response occurs in natural rotavirus infection, and the antibody response appears to be
broad and heterotypic in nature.
Rotavirus accounts for ∼800,000 child deaths world-
wide annually [1]. An improved understanding of im-
munity against specific rotavirus proteins will accelerate
development and evaluation of new candidate vaccines.
This is particularly important now, because of the with-
drawal of a licensed reassortant rotavirus vaccine due
to a reported increased risk of intussusception [2, 3].
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Whether the neutralizing proteins VP4 and VP7 play
an important role in induction of protective immunity
against rotavirus-associated diarrhea remains contro-
versial. Extensive field trials of rhesus rotavirus–based
quadrivalent vaccine, conducted in different popula-
tions and in various parts of the world, have demon-
strated, in the target population, a high efficacy of the
vaccine against severe diarrhea caused by G serotypes
of epidemiologic importance (G1–G4), and these trials
have thus provided strong support for a serotype-spe-
cific immunity [4–8]. In clinical trials, however, anti-
bodies to the neutralizing antigens did not correlate
well with clinical protection [9, 10]. In recent studies,
the nonneutralizing protein VP6 was shown to protect
mice against rotavirus infection after active or passive
immunizations [11–13].
Nonstructural proteins of Japanese encephalitis virus,
cytomegalovirus, and hepatitis C virus have been shown
to induce protective immunity [14–16]. The involve-
ment of rotavirus nonstructural protein 4 (NSP4) in
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rotavirus pathogenesis was first shown by use of rotavirus reas-
sortants in a gnotobiotic piglet model [17]. After that, this
protein was identified as an enterotoxin on the basis of its ability
to induce diarrhea in infant mice when challenged with infec-
tious virus [18–21]. In neonatal mice, antibodies to NSP4 re-
duced severity of diarrhea caused by infection with either sim-
ian rotavirus or a highly virulent murine rotavirus [18, 19].
Furthermore, a plant-based multicomponent vaccine contain-
ing NSP4 was found to protect mice from enteric disease [22].
Several in vitro studies have also suggested that NSP4 plays a
role in rotavirus pathogenesis [23–25].
Antibody response to NSP4 in humans has been assessed in
a few studies with small numbers of subjects [26, 27]. An IgG,
but not an IgA, antibody response was observed after natural
infection [27]. Because there is a possibility that NSP4-induced
immunity may be involved in protection against rotavirus di-
arrhea, it is important to clearly establish whether such im-
munity develops during natural infection in children and to
relate immune response to the characteristics of the infecting
rotavirus strains.
In this study, we evaluate IgG and IgA antibody responses to
NSP4 in children with rotavirus and nonrotavirus acute gastro-
enteritis and dehydration; we used various glutathione S–trans-
ferase (GST)–NSP4 fusion proteins as antigens in an ELISA. We
also compared the immune response to NSP4 genotypes of in-
fecting strains.
SUBJECTS, MATERIALS, AND METHODS
Subjects and serum samples. The group of study subjects
comprised 70 children with acute watery diarrhea and dehy-
dration who were admitted at All India Institute of Medical
Sciences (AIIMS), New Delhi, India. Their average age (SD)
was 9.8 (4.69) months. Stool samples and acute-phase se-
rum samples were obtained within 72 h of the onset of diarrhea.
Stools were tested for rotavirus by ELISA, as described elsewhere
[28]. Convalescent-phase serum samples were collected 2–3
weeks later. Both stool samples and serum samples were stored
at 20C, until analyzed.
Rotavirus strains. The human 116E rotavirus strain used
for cloning NSP4 was originally isolated, in the neonatal unit
of AIIMS, from feces of a newborn with asymptomatic rotavi-
rus infection and was adapted to grow in cell culture by serial
passage in MA104 cells [29]. Other rotavirus strains (SA11 and
RRV) used in the study were obtained from the Centers for
Disease Control and Prevention.
Reverse transcription–polymerase chain reaction (RT-PCR)
and NSP4 typing assay. Rotavirus double-stranded RNA was
extracted from either stools or infected cell cultures and was used
for determination of G, P, and NSP4 genotype of infecting ro-
tavirus strains. G and P types were determined by RT-PCR, by
use of primers specific for G1–4 and G9 (G type) or for P4, P6,
P8, and P11 (P type) [28, 30]. An RT-PCR method was also used
to determine NSP4 genotype. Oligonucleotide primers specific
for NSP4 genes were synthesized complementary to the 3′ ends
of both viral RNA strands. A consensus primer (ConF4) was
used to reverse transcribe NSP4 RNA, and 3 type-specific prim-
ers—NSP4-TA, NSP4-TB, and NSP4-TC—corresponding to ge-
notypes A, B, and C were used as the pool of primers in the
PCR amplification for typing assay. Positions and sequences of
these primers (5′–3′) were as follows: ConF4 (nt 120–140), GATC-
CTGGAATGGCGTATTTT; NSP4-TA (nt 710–729), TCAGCA-
CCGGACGTTAATGG; NSP4-TB (nt 475–495), CGAAGGAAT-
TCAATCAGAAAA; NSP4-TC (nt 251–272), CTGCATTGTG-
TCAATTTTTAAC. In brief, 1–5 mL of dsRNA was mixed with
2 mL of ConF4 primer (25 mM) and was denatured for 5 min
at 97C. RT was done for 45 min at 42C in 50 mL final reaction
volume. The cDNA was then subjected to 30 PCR amplification
cycles.
Construction of recombinant expression vectors and puri-
fication of rNSP4 proteins. The truncated regions of NSP4
that correspond to amino acid residues 81–175 (SA11), 83–175
(116E), and 78–175 (RRV) were generated by RT-PCR with
respective primer pairs and was cloned into the SmaI/NotI
cut pGEX-5X1 expression vector (Amersham Pharmacia Bio-
tech) [31]. GST protein and GST-SA11 NSP483–175, GST-116E
NSP481–175, and GST-RRV NSP478–175 fusion proteins were ex-
pressed and purified by a method described elsewhere by Ma
et al. [32]. Cultures of DH5 a transformed with recombinant/
nonrecombinant pGEX-5X-1 were induced with 0.1 mM iso-
propyl thio-b-d-galactoside (IPTG), and, after 2 h, cells were
harvested and pellets were resuspended in a 1/50 volume of
PBS. After sonication, Triton X-100 was added to the cell lysate,
at a final concentration of 1%, and cell debris was removed by
centrifugation at 8200 g at 4C. Four milliliters of 50% glu-
tathione–Sepharose 4B was added to 100 mL of sonicate, and
the resultant mixture was incubated with gentle agitation for
1 h at room temperature. After the mixture was washed ex-
tensively with PBS, proteins were eluted with an equal volume
of 10 mM reduced glutathione in 50 mM Tris-HCl (pH 8.0).
Protein concentrations were determined by use of a standard
protein assay kit. rNSP4s were confirmed by nucleotide se-
quencing of the insert, by use of a T7 sequencing kit (Amer-
sham Pharmacia Biotech) [32] and also by immunoblotting
with specific serum samples.
SDS-PAGE and Western blot analysis of recombinant
NSP4s. Uninduced and induced culture lysates of the recom-
binant clones and affinity-purified GST-NSP4s and GST proteins
were fractionated by electrophoresis on a 10% SDS-polyacryl-
amide gel. Proteins were visualized by staining with Coomassie
brilliant blue R-250. For immunoblotting, 2–5 mg each of purified
GST, GST-NSP4 fusion proteins, and tissue culture lysate (SA11
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Figure 1. SDS-PAGE analysis of SA11 GST-nonstructural protein 4
(NSP4)83–175 (lanes 2–4), 116E GST-NSP481–175 (lanes 5–7), and RRV GST-
NSP478–175 (lanes 8–10) fusion proteins from uninduced (U) and induced
(I) Escherichia coli culture lysates and purified fusion protein (P) and
purified GST (G), from E. coli extracts. Positions of GST-NSP4 and GST
proteins are noted with arrows. M, molecular weight markers.
Figure 2. Confirmation of SA11 GST-nonstructural protein 4 (NSP4)83–175, 116E GST-NSP481–175, and RRV GST-NSP478–175 fusion proteins and GST
protein, purified from isopropyl thio-b-D-galactoside–induced Escherichia coli cell lysates, by immunoblotting with anti-GST rabbit serum samples (A)
and anti-rotavirus human serum samples (B). Reactivity with SA11-infected (RV) and mock-infected (mock) tissue culture lysates is shown in rightmost
lanes in B.
infected or mock infected) were fractionated on a 10% SDS-
polyacrylamide gel and then were transferred to polyvinylidene
fluoride membrane (Millipore). The membranes were probed
with either anti-GST antibody or known anti-rotavirus human
serum samples (1:500), and, correspondingly, alkaline phospha-
tase–conjugated anti-rabbit or anti-human IgG/IgA was used to
develop the respective blots. To visualize the antibodies bound
to the proteins, 5-bromo-4-chloro-3-inodlyl phospahte and ni-
troblue tetrazolium were used as enzyme substrates [32, 33].
IgA and IgG ELISA. For NSP4 antibody assays, 96-well
microtiter plates with high binding capacity (Costar) were coated
overnight at 4C with either GST-NSP4 (1 mg/well) or GST (0.7
mg/well), in 100 mL of 0.1 M carbonate-bicarbonate buffer (pH
9.6). To generate a standard curve, serial 2-fold dilutions of 1:
100–1:12,800 (i.e., 100–0.78 U/mL) of known anti-rotavirus hu-
man serum samples were added to duplicate wells coated with
either GST-NSP4 or GST. The concentration of NSP4 IgG or
IgA antibody in the reference serum samples was arbitrarily as-
signed a value of 10,000 U/mL. Patient serum samples that were
to be tested were also added to duplicate wells containing GST-
NSP4 (SA11, 116E, or RRV) or GST protein. Paired serum from
each patient was tested in the same plate at a 1:100 or higher
dilution. All dilutions of antibodies and conjugates were made
in PBS-Tween containing 1% skim milk. After addition of se-
rum, plates were incubated for 2–3 h at room temperature. For
IgG ELISA, horseradish peroxidase–conjugated anti-human IgG
(Jackson ImmunoResearch laboratories) was added; for IgA
ELISA, biotin-conjugated anti-human IgA (Jackson Immuno-
Research laboratories) and horseradish peroxidase–conjugated
avidin-biotin (Vector Laboratories) were added, according to the
manufacturers’ protocols or as described elsewhere [34]. Color
was developed with o-phenylenediamine substrate (Sigma), and
optical density was measured as absorbance at 490 nm (A490).
Antibody titers (IgA and IgG) were expressed as units per mil-
liliter of serum; values were determined from a standard line
plot of the reference serum samples, after subtraction of the
average A490 values of duplicate wells coated with GST from those
with NSP4-GST. In each plate, both a known positive and neg-
ative control serum were included, and the assay was regarded
to be valid only when negative sample was clearly negative and
positive sample was within 2-fold of its assigned value [34].
Seroconversion was defined as a 4-fold rise in antibody titer
between acute and convalescent serum samples. Titers of IgG
and IgA antibody, to whole rotavirus, were determined by ELISA,
as described by McNeal et al. [34]. Tissue culture lysate from
either SA11-infected cells or mock-infected cells was used as
coating antigen. Antibody titers were expressed as units per mil-
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Figure 3. Immunoblotting of GST-nonstructural protein 4 (NSP4) A, NSP4B, and NSP4C, with convalescent serum samples from 6 children infected
with rotavirus—3 infected with strain NSP4A (A, lanes 1–3) and 3 with NSP4B (B, lanes 4–6)—tested at 2 different dilutions (bottom), against equal
amounts of NSP4A (A), NSP4B (B), NSP4C (C), and GST (G) antigens.
liliter; values were determined from the standard curve [34]. The
limits of detection were 156, 156, 78, and 78 units/mL for serum
NSP4 IgG, NSP4 IgA, whole rotavirus IgG, and whole rotavirus
IgA, respectively, and these values were used to calculate geo-
metric mean titers when antibody titers were below the limit of
detection.
Statistical analysis. Data were analyzed by Stata (version
7; Stata). Categorical variables were compared by x2 test. An-
tibody titers were log transformed, and geometric mean anti-
body titers of different groups were compared by analysis of
variance. was considered significant.P ! .05
RESULTS
Cloning, expression, and purification of GST-NSP4 fusion pro-
teins. Because expression of full-length NSP4 in Escherich-
ia coli was unsuccessful, truncated proteins SA11-NSP483–175,
116E-NSP481–175, and RRV-NSP478–175, representing genotypes A,
B, and C, respectively, were expressed in E. coli as GST-NSP4
fusion proteins. SDS-PAGE analysis of whole cell lysates from
IPTG-uninduced and IPTG-induced culture-purified and af-
finity-purified GST-NSP4 fusion proteins and from GST are
shown in figure 1. All of the fusion proteins (SA11, 116E, and
RRV) are clearly seen as ∼38-kDa bands, and the GST protein
as a 26-kDa band, in the IPTG-induced culture lysate (figure
1). A high level of expression (5–15 mg/L of bacterial culture)
was obtained with each of the GST-NSP4 fusion proteins.
Confirmation of rNSP4 proteins by immunoblotting.
Identities of GST-NSP4 fusion proteins were confirmed by im-
munoblotting with anti-GST rabbit serum samples and anti-
rotavirus human serum samples (figure 2). Although anti-GST
serum samples bound with equal intensity to all GST-NSP4s
and to the GST protein (figure 2), human serum samples (1:
500 dilution) reacted specifically with 38-kDa GST-NSP4s, and
not with 26-kDa GST, in the immunoblot developed with either
anti-human IgG conjugate (figure 2) or anti-human IgA con-
jugate (result not shown). As expected, human serum samples
also specifically bound to various rotavirus proteins present in
rotavirus-infected tissue culture lysate (figure 2).
IgG and IgA antibody response to NSP4 in children with
rotavirus and nonrotavirus gastroenteritis. The rotavirus-in-
fected children showed significantly higher IgG and IgA sero-
conversion rates to each rNSP4 tested than did rotavirus-unin-
fected children. The IgG seroconversion rates in rotavirus-in-
fected children were 67.5%, 70%, and 60% when rNSP4A,
rNSP4B, and rNSP4C, respectively, were used as antigen in the
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Table 1. Seroconversion in rotavirus-infected and rotavirus-uninfected children,
determined by use of various recombinant nonstructural protein 4 (NSP4) antigens
in ELISA.
Response, patient group
No. of
subjects
Antigen
NSP4A NSP4B NSP4C
Whole
rotavirus
IgG
Rotavirus-infected 40 27 (67) 28 (70) 24 (60) 31 (77)
Rotavirus-uninfected 30 3 (10) 4 (13) 2 (7) 4 (13)
IgA
Rotavirus-infected 40 23 (57) 28 (70) 20 (50) 29 (72)
Rotavirus-uninfected 30 1 1 1 3
NOTE. Data are no. (%) with response to antigen by ELISA. All comparisons between rotavirus-
infected and rotavirus-uninfected groups were significant ( ).P ! .001
Table 2. Seroconversion rates in children with acute
rotavirus gastroenteritis, with or without detectable an-
tibodies to either whole rotavirus or rotavirus nonstruc-
tural protein 4 (NSP4), at baseline.
Baseline
antibody
No. of
subjects
NSP4
(1 antigen)
Whole
rotavirus
Detectable 22 12 (55)a 16 (73)b
Not detectable 18 17 (94) 15 (83)
NOTE. Data are no. (%) of children who seroconverted to
antigen.
a .Pp .005
b .Pp .424
assay, and the corresponding rates for rotavirus-uninfected chil-
dren were 10%, 13%, and 7%, respectively (table 1). The rate of
IgA seroconversion was 57.5%, 70%, and 50% in rotavirus-in-
fected children when rNSP4A, rNSP4B, or rNSP4C, respectively,
were tested in the ELISA. Among rotavirus-uninfected children,
only 1 seroconverted to each rNSP4 (table 1). Furthermore, 34
(85%) of 40 rotavirus-infected children who were examined
showed 2-fold rises in IgG or IgA antibody titer to 1 GST-
NSP4. A high rate of IgG (77.5%) and IgA (72.5%) serocon-
version to whole rotavirus was also observed in rotavirus-infected
children (table 1).
We assessed the effect that prior exposure to rotavirus in-
fection has on immune response during natural rotavirus in-
fection. For this analysis, detectable IgG and IgA antibody to
both NSP4 and whole rotavirus, in the baseline serum, con-
stituted evidence of prior exposure to rotavirus. Within the
group of 40 children with rotavirus gastroenteritis, the sero-
conversion rate to NSP4 was significantly lower among those
with prior exposure to rotavirus than it was among children
without detectable baseline antibody ( ). The serocon-Pp .005
version rate to whole rotavirus was similar in children with
and children without detectable baseline antibody (table 2).
NSP4 antibody response in relation to NSP4 genotype of
infecting strain. Among 40 rotavirus-infected children,
NSP4 genotype was determined in samples from 27 (9 geno-
type A [8G2 and 1G1] and 18 genotype B [6G9 and 5G1]). Of
9 children infected with NSP4A strains, 5 showed IgG sero-
conversion to all GST-NSP4 antigens tested in the ELISA; 1
child seroconverted to NSP4A and NSP4B but did not sero-
convert to NSP4C, and 1 other child seroconverted only to
NSP4A. In children infected with NSP4B strains, 15 of 18
showed seroconversion to rNSP4A, rNSP4B, and rNSP4C. One
child showed seroconversion only when NSP4B was used in
the ELISA (table 3). The findings, with regard to IgA response
and in relation to NSP4 type of the infecting strain, were simi-
lar to those for IgG antibody (table 3).
We also assessed the magnitude of antibody response in re-
lation to NSP4 genotype of the infecting strain. The geometric
mean IgG or IgA antibody titers of the 9 children infected with
NSP4A strains, compared with those of 18 children infected
with NSP4B strains, were not significantly different when any
of the 3 rNSP4s were used in the ELISA (table 4).
Convalescent serum samples from 6 children (NSP4 serocon-
verted), 3 infected with NSP4A and 3 with NSP4B strains, were
also tested in immunoblots with GST-NSP4A, GST-NSP4B, and
GST-NSP4C antigens in equal amounts. All 6 samples reacted
strongly to NSP4A, NSP4B, and NSP4C antigens when tested at
lower dilutions of serum (figure 3). Some variability in the reac-
tivity of serum samples with different rNSP4s was observed when
serum samples were tested at higher dilutions (figure 3).
DISCUSSION
The main findings from this study are that natural rotavirus
infection results in a significant NSP4-specific IgG and IgA an-
tibody response in children and that the immune response is
essentially similar in the presence of infection with strains of
different NSP4 genotypes. In a study by Johansen et al. [27], IgG
antibodies to NSP4 were found in convalescent serum samples
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Table 3. Antibody response to nonstructural protein 4
(NSP4), according to NSP4 genotype of infecting rotavirus.
Response,
genotype
No. of
subjects rNSP4A rNSP4B rNSP4C All 3
IgG
A 9 7 6 5 5
B 18 16 17 15 15
IgA
A 9 6 6 5 5
B 18 11 14 11 10
NOTE. Data are no. with seroconversion to recombinant (r) antigen
in ELISA.
Table 4. IgG and IgA antibody titer, according to nonstructural protein 4 (NSP4) genotype
of infecting rotavirus strain.
Genotype
IgG response IgA response
NSP4A (n p 9) NSP4B (n p 18) NSP4A (n p 9) NSP4B (n p 18)
rNSP4A 1686 (437–6503) 1633 (889–3011) 1426 (229–8889) 536 (213–1348)
rNSP4B 2168 (572–8184) 2771 (1437–5324) 1415 (287–6986) 1291 (506–3289)
rMSP4C 1541 (493–4817) 1628 (898–2981) 976 (268–3548) 626 (300–1305)
NOTE. Data are geometric mean titer (95% confidence interval) of antibody to recombinant (r) antigen
in children infected with particular genotype. Comparisons were not statistically significant by analysis of
variance: infecting strain NSP4A, IgG or IgA ( for each); infecting strain NSP4B IgG ( ) or IgAPp .9 Pp .1
( ).Pp .3
of all 10 children examined. Baseline antibody levels, and there-
fore seroconversion rates, were not reported in that study.
Unlike in the present study, Johansen et al. [27] did not
detect IgA antibodies to either NSP4 or VP6 in the limited
number of rotavirus-infected children they examined, by use
of SA11 NSP4 or VP6 antigen expressed in insect cells, in the
ELISA [27]. The inconsistency between the studies may be
related to differences in antigens used or other assay conditions.
A few children whose stools were negative for rotavirus but
who showed antibody response to NSP4 and to whole rotavirus
were, in all probability, rotavirus infected. Stool negativity may
have resulted from less-than-maximal sensitivity of the detec-
tion kit used. Alternatively, the observed antibody response may
be due to anamnestic response to rotavirus proteins in those
children.
The less frequent seroconversion to NSP4, and not to whole
rotavirus, in children with prior rotavirus exposure is of in-
terest. Prior exposure (preexisting antibodies) to rotavirus may
limit replication of virus in the intestinal cells, and this is more
likely to affect immune responses to nonstructural proteins.
Sequence analysis of rotavirus NSP4 from human and animal
strains has revealed the presence of 4 distinct NSP4 alleles (A,
B, C, and D) or genetic groups (I, II, III, and IV); the majority
of human strains were classified as either genogroup I (genotype
A) or genogroup II (genotype B) [35]. It has been postulated
that antigenic differences between NSP4s from different in-
fecting rotavirus strains may affect immune responses after
infection. In a study by Richardson et al. [26], NSP4 antibody
response in children with G1 rotavirus infection varied between
67% and 100%, depending on the rotavirus strain used as
antigen in the assay. Furthermore, NSP4 from a G2 strain was
not immunoprecipitated by any serum sample from children
infected with G4 strain, but it was recognized by 67% of samples
from children infected with G1 rotavirus.
Our data suggest that the NSP4 antibody response is not sig-
nificantly influenced by NSP4 genotype of the infecting strains.
IgG or IgA seroconversion rates or geometric mean antibody
titers in convalescent serum samples of rotavirus gastroenteritis
patients, whether infected with NSP4 genotype A or B strains,
were similar when the same NSP4 antigen was used in the assay.
Our data indicate that the NSP4 antibody response is heterotypic
in nature, because the immune response did not vary among
children, irrespective of whether NSP4A, NSP4B, or NSP4C was
used as antigen in the assay. In a recent study, Estes et al. [19]
observed heterotypic protection against rotavirus diarrhea in
mice. A heterotypic immune response to NSP4 would be ad-
vantageous for vaccine development in the event that NSP4-
induced antibody response turns out to be, in future studies,
protective in nature. One potential limitation related to this ob-
servation is that baseline antibody levels may not completely
differentiate children as having had either prior exposure or a
lack of it. Therefore, a naive gnotobiotic animal system may be
a suitable model to analyze true primary and secondary homo-
typic and heterotypic serum IgG and IgA antibody responses to
NSP4 protein [36].
NSP4-specific antibody responses were also observed in a
limited number of subjects immunized with rhesus rotavirus–
tetravalent vaccine [27]. As with natural infection, the NSP4-
specific IgG antibody response was of a lower magnitude than
was that to VP6. The study involved too few subjects to be
able to determine whether NSP4 antibody induced by im-
munization protects against subsequent rotavirus infection or
against diarrhea [27]. Future vaccine trials may provide an ideal
opportunity to address this issue.
In conclusion, our findings indicate that, during natural ro-
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tavirus infection in children, NSP4 IgG and also IgA antibody
responses are induced in a majority of cases. Of potential im-
portance for vaccine development, the magnitude of the an-
tibody response is not significantly affected by the genotype of
the infecting strain, and it appears to be heterotypic in nature.
A priority now is to assess mucosal immune responses to NSP4
and to determine whether the NSP4 immune response protects
against all or severe rotavirus diarrhea.
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